rs121913507
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Dasatinib overrides the differentiation blockage in a patient with mutant-<i>KIT</i> D816V positive CBFβ-MYH11 leukemia.
|
29545943 |
2018 |
rs121913682
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Dasatinib overrides the differentiation blockage in a patient with mutant-<i>KIT</i> D816V positive CBFβ-MYH11 leukemia.
|
29545943 |
2018 |
rs121913507
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Asp816Val mutation was found in 3.5% of cases of AML and Val560Gly mutation in 1 sample with acute biclonal leukemia.
|
25247397 |
2015 |
rs121913682
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Asp816Val mutation was found in 3.5% of cases of AML and Val560Gly mutation in 1 sample with acute biclonal leukemia.
|
25247397 |
2015 |
rs121913507
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In most patients with systemic mastocytosis (SM), including aggressive SM (ASM) and mast cell (MC) leukemia (MCL), neoplastic cells express the oncogenic KIT mutation D816V, which confers resistance to imatinib.
|
20553795 |
2010 |
rs121913682
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In most patients with systemic mastocytosis (SM), including aggressive SM (ASM) and mast cell (MC) leukemia (MCL), neoplastic cells express the oncogenic KIT mutation D816V, which confers resistance to imatinib.
|
20553795 |
2010 |
rs121913507
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In attempting to establish a murine model of human KIT(D816V) (hKIT(D816V))-mediated leukemia, we uncovered an unexpected relationship between cellular transformation and intracellular trafficking.
|
17060458 |
2007 |
rs121913682
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In attempting to establish a murine model of human KIT(D816V) (hKIT(D816V))-mediated leukemia, we uncovered an unexpected relationship between cellular transformation and intracellular trafficking.
|
17060458 |
2007 |
rs121913514
|
|
|
0.030 |
GeneticVariation |
BEFREE |
N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
|
31484543 |
2019 |
rs748843032
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
|
28810255 |
2017 |
rs25487
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The current meta-analysis indicated that the Arg399Gln polymorphism in the XRCC1 gene might be a risk factor for hematological malignancies in Asians or for leukemia.
|
25619474 |
2015 |
rs25487
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Collectively, the results of the present study suggest that XRCC1 Arg399Gln polymorphism might be a low-penetrant risk factor for leukemia, particularly among Asians.
|
23990457 |
2014 |
rs25487
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Through computerized searching of PubMed, ISI Web of Knowledge, Cochrane, EBSCO, and OpenGrey databases, and manually searching relevant references, a total of 19 studies with 3387 cases and 6168 controls for Arg399Gln (G>A) polymorphism, 12 studies with 2043 cases and 4550 controls for Arg194Trp (C>T), and 6 studies with 1445 cases and 1905 controls for Arg280His (G>A) were collected to perform meta-analysis and stratified analysis to explore the associations between these variants and leukemia susceptibility.
|
24363792 |
2013 |
rs748843032
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Given the fact that all AKIs fail to inhibit BCR/ABL harboring the 'gatekeeper' mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia.
|
22985168 |
2012 |
rs121913514
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Furthermore, dasatinib prolonged lifespan of mice bearing AE and HyC-KIT N822K-coexpressing leukemic cells and exerted synergic effects while combined with cytarabine, thus providing a potential therapeutic for t(8;21) leukemia.
|
21262832 |
2011 |
rs121913514
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Here we studied the effects of Bacillus intermedius RNase (binase) on murine myeloid progenitor cells FDC-P1; transduced FDC-P1 cells ectopically expressing mutated human KIT N822K oncogene and/or human AML1-ETO oncogene; and human leukemia Kasumi-1 cells expressing both of these oncogenes.
|
22101339 |
2011 |
rs748843032
|
|
|
0.030 |
GeneticVariation |
BEFREE |
KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukemia patients.
|
19541823 |
2009 |
rs1800562
|
|
|
0.030 |
GeneticVariation |
BEFREE |
HFE-codon 63/282 (H63D/C282Y) gene variants in Mexican Mestizos are not risk factors for leukemia.
|
16314188 |
2006 |
rs1800562
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Interactions of HFE with environmental and genetic factors, most of which are recognized, may play a role in modification of susceptibility to leu</span>kemia conferred by C282Y.
|
15775751 |
2005 |
rs1800562
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Its male-specificity, occurrence in childhood and the lack of a gene-dosage effect suggest that the C282Y association in childhood ALL may reflect the involvement of another HLA-linked gene in leukemia susceptibility.
|
12002748 |
2002 |
rs121913521
|
|
|
0.020 |
GeneticVariation |
BEFREE |
N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells.
|
31484543 |
2019 |
rs113488022
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results confirm that BRAF V600E-positive HCL is a relatively rare disorder in the Japanese leukemia patient population.
|
30043333 |
2018 |
rs121913377
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results confirm that BRAF V600E-positive HCL is a relatively rare disorder in the Japanese leukemia patient population.
|
30043333 |
2018 |
rs1360131632
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Collectively, the present results suggest that in the treatment of leukemia, taxodione has potential as a compound with high efficacy to overcome BCR-ABL T315I mutation-mediated resistance in leukemia cells.
|
29859988 |
2018 |
rs1799782
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Progression to secondary myelofibrosis/leukemia is influenced by exposure to cytoreductive agents, and caspase and BER polymorphisms {globally, CASP8 3'untranslated region [odds ratio (OR)=0.24; 95% confidence interval (CI), 0.08‑0.69], XRCC1 Arg194Trp [OR=3.58; 95% CI, 0.98‑13.01]; for essential thrombocythemia patients CASP9 Arg173His [OR=11.27; 95% CI, 1.13‑112.28], APEX1 Asp148Glu [OR=0.28; 95% CI, 0.74‑1.03], and XRCC1 Arg194Trp [OR=6.60; 95% CI, 1.60‑27.06]}.
|
30320340 |
2018 |